echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Anke Biotech's PA3-17 injection was approved for clinical use

    Anke Biotech's PA3-17 injection was approved for clinical use

    • Last Update: 2021-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 9th, Anke Biological issued an announcement stating that its shareholding company, Boshengji, received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, agreeing to carry out the treatment of adult relapsed/refractory CD7 positive blood Clinical trials for malignant tumors of the lymphatic system


    This clinical trial approval is the first international nanobody-based CD7-CAR-T cell injection (development code: PA3-17 injection) independently developed by Boshengji Company.


    Most of the CD7-positive malignant tumors are highly aggressive lymphomas or leukemias.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.